132 related articles for article (PubMed ID: 34044070)
41. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle.
Flores-Alcantar A; Gonzalez-Sandoval A; Escalante-Alcalde D; Lomelí H
Cell Tissue Res; 2011 Jul; 345(1):137-48. PubMed ID: 21647563
[TBL] [Abstract][Full Text] [Related]
42. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
[TBL] [Abstract][Full Text] [Related]
43. Low Arid1a Expression Correlates with Poor Prognosis and Promotes Cell Proliferation and Metastasis in Osteosarcoma.
Xu N; Wang L; Sun P; Xu S; Fu S; Sun Z
Pathol Oncol Res; 2019 Jul; 25(3):875-881. PubMed ID: 29177569
[TBL] [Abstract][Full Text] [Related]
44. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
45. ARID1A-deficient cells require HDAC6 for progression of endometrial carcinoma.
Megino-Luque C; Sisó P; Mota-Martorell N; Navaridas R; de la Rosa I; Urdanibia I; Albertí-Valls M; Santacana M; Pinyol M; Bonifaci N; Macià A; Llobet-Navas D; Gatius S; Matias-Guiu X; Eritja N
Mol Oncol; 2022 Jun; 16(11):2235-2259. PubMed ID: 35167193
[TBL] [Abstract][Full Text] [Related]
46. A CRISPR/Cas9-Engineered
Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
[TBL] [Abstract][Full Text] [Related]
47. Role of karyopherin nuclear transport receptors in nuclear transport by nuclear trafficking peptide.
Teratake Y; Kimura Y; Ishizaka Y
Exp Cell Res; 2021 Dec; 409(1):112893. PubMed ID: 34695436
[TBL] [Abstract][Full Text] [Related]
48. Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma.
Zhou H; Tan S; Li H; Lin X
Mol Med Rep; 2019 Mar; 19(3):2125-2136. PubMed ID: 30747208
[TBL] [Abstract][Full Text] [Related]
49. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
[TBL] [Abstract][Full Text] [Related]
50. MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A.
Wang N; Zhou Y; Zheng L; Li H
Gynecol Oncol; 2014 Jul; 134(1):129-37. PubMed ID: 24793973
[TBL] [Abstract][Full Text] [Related]
51. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
52. Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer.
Sun X; Wang SC; Wei Y; Luo X; Jia Y; Li L; Gopal P; Zhu M; Nassour I; Chuang JC; Maples T; Celen C; Nguyen LH; Wu L; Fu S; Li W; Hui L; Tian F; Ji Y; Zhang S; Sorouri M; Hwang TH; Letzig L; James L; Wang Z; Yopp AC; Singal AG; Zhu H
Cancer Cell; 2017 Nov; 32(5):574-589.e6. PubMed ID: 29136504
[TBL] [Abstract][Full Text] [Related]
53. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
[TBL] [Abstract][Full Text] [Related]
54. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
Suryo Rahmanto Y; Jung JG; Wu RC; Kobayashi Y; Heaphy CM; Meeker AK; Wang TL; Shih IeM
J Biol Chem; 2016 Apr; 291(18):9690-9. PubMed ID: 26953344
[TBL] [Abstract][Full Text] [Related]
55. miR-7641 depletion suppresses proliferation of gastric cancer cells by targeting ARID1A.
Yang Y; Yin ZX; Wang ZY; Tian SB; Wang HC; Zhang FX; Li LP; Zheng C; Kong S
Anticancer Drugs; 2020 Apr; 31(4):368-376. PubMed ID: 31913196
[TBL] [Abstract][Full Text] [Related]
56. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
[TBL] [Abstract][Full Text] [Related]
57. Expression of ARID1A in polycystic ovary syndrome and its effect on the proliferation and apoptosis of ovarian granulosa cells.
Ji XL; Liu X; Wang Z; Fang YC
Ann Endocrinol (Paris); 2020 Dec; 81(6):521-529. PubMed ID: 33290750
[TBL] [Abstract][Full Text] [Related]
58. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
59. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
60. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
